Funding: Provided by Gilead Sciences Inc.
USE OF 3′-DEOXY-3′-[18F]FLUOROTHYMIDINE PET/CT FOR EVALUATING RESPONSE TO CYTOTOXIC CHEMOTHERAPY IN DOGS WITH NON-HODGKIN'S LYMPHOMA
Article first published online: 26 OCT 2009
© Copyright 2009 by the American College of Veterinary Radiology
Veterinary Radiology & Ultrasound
Volume 50, Issue 6, pages 660–668, November/December 2009
How to Cite
LAWRENCE, J., VANDERHOEK, M., BARBEE, D., JERAJ, R., TUMAS, D. B. and VAIL, D. M. (2009), USE OF 3′-DEOXY-3′-[18F]FLUOROTHYMIDINE PET/CT FOR EVALUATING RESPONSE TO CYTOTOXIC CHEMOTHERAPY IN DOGS WITH NON-HODGKIN'S LYMPHOMA. Veterinary Radiology & Ultrasound, 50: 660–668. doi: 10.1111/j.1740-8261.2009.01612.x
Material presented in part: Veterinary Cancer Society 2007 (Ft. Lauderdale, FL) and American College of Veterinary Radiology 2008 (San Antonio, TX).
- Issue published online: 26 OCT 2009
- Article first published online: 26 OCT 2009
- Received May 17, 2009; accepted for publication June 24, 2009.
- 3′-deoxy-3′[18F] fluorothymidine;
- non-Hodgkin's lymphoma;
- positron emission tomography
Imaging and measurement of proliferation with computed tomography (CT) and positron emission tomography (PET) provide a noninvasive method for improved staging and monitoring of response to cancer treatment. We evaluated prospectively the proliferation marker 3′-deoxy-3′[18F] fluorothymidine (FLT) in the context of FLT-PET/CT for detection of early response, confirmation of posttreatment response, and prediction of relapse in dogs with non-Hodgkin's lymphoma. Nine dogs with non-Hodgkin's lymphoma who were scheduled to receive five cycles of an investigational cytotoxic chemotherapy agent were included. All dogs received baseline FLT-PET/CT imaging immediately before chemotherapy. Intent was to repeat imaging with FLT-PET/CT at various time points: group 1 (n=4), 5 days after initiation of chemotherapy and 3 weeks following the last chemotherapy administration; group 2 (n=5), before the fourth cycle of chemotherapy and 3 weeks following the last administration. Two dogs in group 2 did not undergo repeat PET/CT. Body mass standardized uptake values (SUV) for FLT were calculated for each dog. Eight dogs had initially increased FLT uptake (mean SUVmax=9.8 [2.6–22.3]). Mean SUV decreased significantly for the seven dogs that underwent follow-up PET/CT following chemotherapy (mean SUVmax=3.5 [1.1–7.9], P<0.016). Increased uptake preceded clinical and cytological evidence of relapse in two dogs. Ki-67 immunohistochemistry confirmed decreased proliferation corresponding to decreased SUV in three canine lymph node samples. FLT-PET/CT functional and anatomical imaging shows promise for the evaluation of response to cytotoxic chemotherapy in dogs with non-Hodgkin's lymphoma and for predicting relapse before standard clinical and clinicopathologic confirmation.